Rechallenge with mTOR Inhibitors in Metastatic Renal Cell Carcinoma Patients Who Progressed on Previous mTOR Inhibitor Therapy

Publisher： Karger

E-ISSN： 1423-0232|85|1|8-13

ISSN： 0030-2414

Source： Oncology, Vol.85, Iss.1, 2013-06, pp. : 8-13

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

mTOR inhibitors in renal cell carcinoma

By Battelli Chiara   Cho Daniel C  

Therapy, Vol. 8, Iss. 4, 2011-07 ,pp. : 359-367

Future Medicine

Access to resources Recommend Favorite

mTOR

By Marin Philippe   Meffre Julie   Bockaert Joël  

Médecine/sciences, Vol. 29, Iss. 1, 2013-01 ,pp. : 28-30

Edp Sciences

Access to resources Recommend Favorite

Mammalian target of rapamycin (mTOR) inhibitor‐associated non‐infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes

By  

BJU INTERNATIONAL, Vol. 113, Iss. 3, 2014-03 ,pp. : 376-382

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy of Sunitinib Re-Exposure after Failure of an mTOR Inhibitor in Patients with Metastatic RCC

By  

Oncology Research and Treatment, Vol. 34, Iss. 6, 2011-05 ,pp. : 310-314

Karger

Access to resources Recommend Favorite

Rhinitis in Patients Treated with a Combination of an mTOR Inhibitor and an EGFR Inhibitor

By  

Oncology Research and Treatment, Vol. 33, Iss. 7, 2010-06 ,pp. : 401-402

Karger

Access to resources Recommend Favorite